Boehringer Ingelheim GmbH has agreed to pay $65 million upfront over four years, plus research funding, to Forma Therapeutics Inc of the US to discover new small molecule drugs for cancer using Forma’s protein-protein interaction technology. ---Subscribe to MedNous to access this article--- Finance, Grants, Deals Company News
